Aclaris Therapeutics, Inc.
ACRS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.04 | 0.18 | 0.70 | -0.27 |
| FCF Yield | -10.54% | -108.64% | -6.64% | -6.36% |
| EV / EBITDA | -3.23 | -0.29 | -11.65 | -12.38 |
| Quality | ||||
| ROIC | -75.20% | -58.10% | -38.51% | -39.18% |
| Gross Margin | 85.09% | 42.14% | 59.80% | 30.29% |
| Cash Conversion Ratio | 0.15 | 0.89 | 0.78 | 0.57 |
| Growth | ||||
| Revenue 3-Year CAGR | -14.31% | 66.57% | 66.19% | 16.95% |
| Free Cash Flow Growth | 74.64% | -16.81% | -30.00% | -34.17% |
| Safety | ||||
| Net Debt / EBITDA | 0.48 | 0.34 | 0.53 | 0.41 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -606.93 | -175.74 | -309.96 | -739.66 |